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Background. Extracellular matrix macromolecules regulate morphogen-
esis of embryonic organs, and are developmentally regulated. Their
expression and turnover is regulated by matrix metalloproteinases
(MMPs). Recently, an epithelial cell “membrane” associated metallopro-
teinase (MT-1-MMP) has been identified that acts as an activator of a
“secreted” MMP-2, and is produced by mesenchymal fibroblasts. The
activity of MMP-2 is inhibited by a “soluble” tissue inhibitor of MMP-2,
TIMP-2. The role of MT-1-MMP in renal development is unknown.
Methods. MT-1-MMP was cloned from embryonic mouse kidney cDNA
library, and its spatio-temporal distribution during development in the
context of MMP-2 and tissue inhibitor of metalloproteinase-2 (TIMP-2)
was studied.
Results. The cloned MT-1-MMP exhibited ;86% nucleotide sequence
homology with human MT-1-MMP, and had a catalytic domain and a zinc
binding site preceded by a RRKR furin recognition motif. A ;4.5 Kb
MT-1-MMP mRNA transcript was detected, and its expression was
developmentally regulated. A parallel developmental regulation of
MMP-2 mRNA expression was also observed. TIMP-2 expression was also
developmentally regulated, but lagged behind MT-1-MMP and MMP-2.
By in situ hybridization, MT-1-MMP mRNA was seen to be confined to
ureteric bud epithelia, and was absent in the mesenchyme, while MMP-2
was confined to the mesenchyme. MT-1-MMP protein expression was
seen on ureteric bud epithelia, induced mesenchyme and nascent
nephrons, and it was highest during mid gestation. Similar spatio-temporal
expressions of MMP-2 and TIMP-2 proteins were observed.
Conclusions. mRNAs of MT-MMP-1 and MMP-2 are expressed in the
respective epithelial and mesenchymal compartments, while their proteins
are co-expressed in the epithelia suggest that MT-1-MMP and MMP-2, in
conjunction with TIMP-2, may be involved in paracrine/juxtacrine epithe-
lial:mesenchymal interactions during metanephrogenesis.
Renal organogenesis constitutes a series of intricate
processes involving differentiation and rapid proliferation
of pluripotent cells during embryonic life. It ensues follow-
ing the reciprocal interaction of epithelial ureteric bud
branches with the loose metanephric mesenchyme, fol-
lowed by inductive conversion of the mesenchyme into an
epithelial phenotype with subsequent formation of nascent
nephrons [1]. These processes are modulated by a diverse
group of macromolecules, including extracellular matrix
(ECM) glycoproteins, their receptors, that is, integrins, and
ECM degrading enzymes and their inhibitors [2–5]. Since
remodeling of the ECM is influenced by ECM-degrading
enzymes, such as MMPs, the latter could be regarded as the
integral component of the process of morphogenesis of
various organ systems that are prototypic of the epithelial:
mesenchymal interactions. These include mammary and
salivary glands, lung and mammalian metanephros [5–7].
Matrix metalloproteinases (MMPs) are zinc metal-de-
pendent proteolytic enzymes, which can collectively de-
grade all the components of the ECM. The MMPs have
been implicated in remodeling of ECM during various
physiological processes and in pathologic states [8–13].
Currently, there are about 17 known MMPs classified into
distinct groups: interstitial collagenases (MMP-1, -8 and
-13), stromelysins (MMP-3, -7 and -10), gelatinases
(MMP-2 and -9), elastases (MMP-12), RXKR secreted
type (MMP-11), and RXKR membrane type-MMPs
(MMP-14, -15, -16 and -17, also known as MT-1-MMP,
MT-2-MMP, MT-3-MMP and MT-4-MMP, respectively)
[10, 14–18]. MMPs of the last two groups share the RXKR
(arginine.arginine/glutamine.lysine.arginine) recognition
motif for the Golgi-associated proteinase, furin [19], which
appears to regulate pro-enzyme processing to active en-
zyme for these two groups [14, 19]. MMPs have common
characteristics that include pre/pro-peptide, hinge, he-
mopexin-like (except MMP-7), and catalytic domains; the
latter domain is the zinc binding site [20].
The gelatinases, MMP-2 and MMP-9, are distinct mem-
bers of the MMP family in that they form pro-enzyme
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complexes with endogenous tissue inhibitors of metallopro-
teinases (TIMPs). Pro-MMP-2 selectively complexes with
TIMP-2, and pro-MMP-9, in monomeric form, complexes
with TIMP-1 [21–23]. The role of these pro-enzyme-inhib-
itor complexes in regulation of ECM turnover is not clear;
however, their formation may account, at least in part, for
selective inhibition of MMP-2 by TIMP-2. A similar selec-
tive inhibition by TIMP-2 has also been reported for
MT-1-MMP [24]. The activation of many of the soluble
MMPs can be initiated by plasmin [25]. The MMP activa-
tion is accompanied by a decrease in molecular mass of
about 8 kD after removal of the pro-fragment. However,
soluble pro-MMP-2 is unique in that this enzyme is not
activated by plasmin in solution, but requires a specific cell
surface mechanism for processing and activation of the
pro-enzyme and pro-enzyme-TIMP-2 complexes [26–29].
These studies subsequently led to the identification of
MT-1-MMP and demonstration that this membrane type
MMP activates the pro-MMP-2 and pro-MMP-2/TIMP-2
complexes [15, 30]. Conceivably, the interaction of these
three components, MT-1-MMP:MMP-2:TIMP-2, may ulti-
mately influence various biological processes related to
ECM remodeling.
Since pro-MMP-2 is expressed in the mesenchymal cells
and MT-1-MMP mainly in the epithelial cells of various
human cancerous tissues, it is therefore conceivable that
paracrine/juxtacrine interactions may be needed in order to
facilitate MT-1-MMP-activation of pro-MMP-2 and initia-
tion of ECM remodeling [31]. Such a scenario could be
ideally suited for epithelial:mesenchymal interactions that
are prevalent during embryonic development. In view of
these considerations, studies were initiated to clone the
murine MT-1-MMP and to investigate its spatio-temporal
distribution, in conjuction with the developmental regula-
tion of MMP-2 and its selective inhibitor TIMP-2 in the
organogenesis of the mammalian embryonic metanephros.
METHODS
Animals
Paired male:female mice mating of ICR® mice (Harlan
Sprague Dawley, Inc., Indianapolis, IN, USA) was carried
out, and fetuses at day-13, day-17 and day-19 (newborn) of
gestation were harvested, and various embryonic organs,
including brain, heart, kidney, liver, lung and placenta were
procured. In addition, kidneys from one-, two- and three-
week-old mice were obtained.
Isolation and characterization of mouse membrane-type
matrix metalloproteinase-1 (MT-1-MMP) cDNA
Initially, a polymerase chain reaction (PCR) product was
generated for screening the embryonic mouse renal cDNA
library [32, 33]. Total RNA from fetal (day-13) and new-
born kidneys was isolated by guanidinium isothiocyanate-
CsCl centrifugation method [34]. Poly(A)1 RNA was se-
lected by oligo(dT) cellulose chromatography. First strand
cDNA was synthesized by using RNase H2 Maloney mu-
rine leukemia virus reverse transcriptase (MMLV-RT), and
the following primers: 59-CCCGATGATGACCGC-
CGGGGCA TCC-39 (sense) and 59-GCGTCTGAAGAA-
GAAGACTGCAAGG-39 (antisense), the sequences of
which were derived from human MT-1-MMP [16]. A 879
bp PCR cDNA product was generated and cloned into
pCRy II plasmid vector (Invitrogen, Carlsbad, CA, USA)
and its nucleotide sequence determined by dideoxynucle-
otide chain-termination method [35], using a DNA se-
quencing kit (Sequenase version 2.0; United States Bio-
chemical Corp., Cleveland, OH, USA). After confirming its
sequence homology with human MT-1-MMP, the 879 bp
cDNA was labeled with [a-32P]dCTP (Amersham Corp.,
Arlington Heights, IL, USA) and used as a probe for
screening of lZAP embryonic and newborn mouse kidney
cDNA libraries. About 0.5 3 106 recombinants were
screened, nitrocellulose filter (Schleicher & Schuell,
Keene, NH, USA) lifts were made, and hybridized with
radiolabeled probe under high stringency conditions, as
previously described [32, 33]. Several clones were iso-
lated, and purified by dilutional secondary and tertiary
screenings. Four purified cDNA clones, which strongly
hybridized with the radiolabeled probe, were subcloned
into pBluescript II SK(-) using SOLR cell by in vivo
excision with ExAssisty Interference-Resistant Helper
Phage of ExAssisty/ SOLRy system (Stratagene, La Jolla,
CA, USA). The inserts of these cDNA clones varied
between 1.2 and 2.0 kb in size (Fig. 1). To generate
single-stranded cDNA, the phagemids containing the in-
serts were subjected to a transformation at 42°C using
XL1-Blue MRF cells, followed by propagation in the
presence of VSCM13 helper phage (Stratagene). Nucleo-
tide sequence analyses of various cDNA inserts were
performed after determining their sense or antisense ori-
entations. Finally, hydropathic [36] and nucleotide se-
quence homology [37] analyses were carried out using
Wisconsin Packagey 8.0.1 (Madison, WI, USA).
Northern blot analyses
Total RNA was extracted from mice kidneys, harvested
during the embryonic (days 213 and 219) and postnatal
periods. In addition, RNA was also extracted from various
organs including brains, hearts, lungs, livers and placenta at
day-19 of gestation. Five micrograms of oligo(dT)-selected
poly(A)1 RNA, from each of the organ, were glyoxalated
and subjected to 1% agarose gel electrophoresis in 10 mM
sodium phosphate buffer, pH 7.0. The electrophoresed
mRNA was transferred to a nylon membrane filter (Amer-
sham Corp.). The nylon membrane mRNA blot was then
hybridized with [a-32P]dCTP-labeled mouse MT-1-MMP
cDNA and b-actin cDNA (GenBank accession # M62174;
ATCCt, Rockville, MD, USA). The same mRNA blots
were hybridized with [a-32P]dCTP-labeled mouse MMP-2
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[38] and TIMP-2 [39] cDNAs. The filter blots were washed
at high stringency conditions with 0.1 3 SSC 1 0.1% SDS
at 60°C, and autoradiograms prepared.
Expression of MT-1-MMP by in situ hybridization
Sense- and antisense-riboprobes of MT-1-MMP cDNA
were prepared by using a Riboprobe In vitro Transcription
System (Promega Co., Madison, WI, USA). A PstI/ApaI
fragment of clone # 4 (Fig. 1, bp 363-1191) in pBluescript
KS(1) was prepared and linearized. Antisense- and sense-
riboprobes were synthesized by incorporating [a-33P]UTP
(Amersham Corp.), using T3 and T7 RNA polymerases.
The radiolabeled riboprobes were subjected to limited
alkaline hydrolysis to yield polynucleotide fragments of 100
to 150 bp size. The fragments were purified by ethanol
precipitation, and used for hybridization with tissue sec-
tions. For mouse MMP-2 and TIMP-2 riboprobes, PCR
DNA products spanning bp1308-1883 (MMP-2, Genbank
accession # m84324) and bp 328-895 (TIMP-2, Genbank
accession # X62622) were generated and utilized.
Fetal (day-13, and day-17) and newborn mice kidneys
were fixed in 4% formaldehyde in PBS, pH 7.0, for three
hours at 4°C. The tissue specimens were then dehydrated in
a graded series of ethanols, and embedded in paraffin. ;3
mm-thick sections were prepared, and mounted on glass
slides, the latter had been acetone-treated and coated with
Vectabondy (Vector Laboratories, Inc., Burlingame, CA,
USA). The sections were deparaffinized, hydrated, treated
with 0.2 N HCl, deproteinated by proteinase K, and acety-
lated with 0.1 M tri-ethanolamine and 0.25% acetic anhy-
dride. After washing sections with 2 3 SSC, they were
prehybridized with hybridization solution (50% formamide,
10% dextran sulfate, Denhardt’s solution in 10 mM Tris-
HCl, pH 8.0) at 50°C for three hours; followed by hybrid-
ization with [a-33P]UTP labeled-MT-1-MMP riboprobes at
50°C for 15 hours. After hybridization, the tissue sections
were washed with 50% formamide 1 2 3 SSC, treated with
RNaseA, and re-washed with 0.1 3 SSC at high stringency
conditions. They were then dehydrated in a graded series of
ethanols, air-dried, coated with NBT2 emulsion (Eastman
Kodak, New Haven, CT, USA), and tissue autoradiograms
prepared after one to two weeks of exposure.
Generation of anti-MT-1-MMP antibody
For generation of anti-MT-1-MMP polyclonal antibody,
a synthetic peptide with the following amino acid sequence,
KVEPGYPKSALR DWMG, was used. Its sequence was
derived from the extracellular domain of the mouse MT-
1-MMP (Fig. 2A, double underline). The peptide was
conjugated at its N-terminal lysine residue with keyhole
limpet hemocyanin. One milligram of conjugated peptide
in 1 ml of PBS was mixed with an equal volume of
incomplete Freund’s adjuvant, and used for immunizing
the rabbit. Booster injections of the conjugated peptide
were given every month, and rabbit antisera collected. IgG
fraction was purified by precipitation at 33.3% saturation of
ammonium sulfate. After extensive dialysis against PBS,
the IgG fraction was lyophilized, and stored at 270°C till
further use. Specificity of the antibody was determined by
enzyme-linked immunosorbent assay (ELISA) and immu-
noprecipitation procedures.
Specificity of the antibody by enzyme-linked
immunosorbent assays
Wells of EIA/RIA plate (Corning Coster Corp., Cam-
bridge, MA, USA) were coated with 50 ml of synthetic
peptide solution (100 mg/ml) in carbonate buffer (20 mM,
pH 9.0). The plates were allowed to dry overnight at 37°C,
and then 100 ml of ice-cold methanol was added to each
well and dried. To reduce nonspecific binding of the
antibody, 200 ml of bovine serum albumin (BSA) solution
(5 mg/ml) in phosphate buffered saline (PBS) was added
and left at 22°C for one hour. Wells were washed twice with
the PBS, and 0.5 mg of antibody (IgG fraction) in 50 ml of
Fig. 1. Schematic drawing of mouse MT-1-
MMP cDNAs (clones # 1 to 4). Open reading
frame flanked by 59- and 39-untranslated
regions (f), transmembrane hydrophobic
segment (u), and initiation and stop codons
(arrows) are indicated. One EcoRI and two
KpnI restriction sites are also indicated. The
bottom gray box represents the partial-length
mouse MT-1-MMP cDNA, which was
generated by reverse transcriptase-polymerase
chain reaction (RT-PCR), and used for
screening of mouse newborn kidney cDNA
library. Arrows flanking the bottom gray box
indicate location of the primers used for
generating the partial-length MT-1-MMP
cDNA by PCR.
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Fig. 2. (A) Nucleotide and deduced amino
acids sequence of full-length mouse renal MT-
1-MMP cDNA. Double underline (5) indicates
amino acid sequence of the synthetic peptide
used for raising the antibody. Bold underline
( ) represents hydrophobic transmembrane
segment. Potential N-linked glycosylation sites
are encircled. Arrow (1) represents the
putative processing site, which is preceded by a
furin recognition motif, RRKR (M). The
shaded box indicates the putative zinc binding
site. (B and C) Kyte and Doolittle
hydrophobicity/hydrophilicity plot analyses of
various hydrophobic segments of mouse MT-1-
MMP. Panel B indicates the analyses of
putative signal peptide (12-25 amino acid
residues) and panel C of the transmembrane
(537-559 amino acid residues) segment of the
MT-1-MMP. Hydrophilicity of the putative
signal peptide and of the hydrophobic
transmembrane segment approaches to 23.0
and 24.0, respectively (GenBank accession
# U54984).
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BSA-PBS (100 ml) solution was added to the first well. Log
dilutions of the antibody were made in successive wells, and
incubation was carried out with gentle shaking for 60
minutes. Wells were re-washed 3 times with PBS containing
0.05% Tween-20. Horseradish peroxidase (HRP)-conju-
gated goat anti-rabbit IgG (Cappel, Organon Teknika
Corp., Durham, NC, USA) diluted 1:1000 in BSA-PBS
solution was added, and incubated for 30 minutes. After
another three washes with PBS-Tween-20, 100 ml of TMB
solution, containing 9 parts of 3,39,59,59-tetramethylbenzi-
dine and 1 part of H2O2 (Bio-Rad Laboratories, Hercules,
CA, USA) was added, and plates were left in the dark for
30 minutes. The colorimetric reaction was stopped by the
adding of 100 ml of 0.3 M H2SO4. Finally, the readings at
OD490 were plotted against the log dilutions of the anti-
body. For competitive inhibition ELISA assay, 250 mg of
the synthetic peptide of MT-1-MMP was added in the first
well of peptide-coated titer plate along with 0.5 mg of the
antibody in 50 ml of PBS-BSA solution. Log dilutions of the
antigen, that is, synthetic peptide, were made in successive
wells while keeping a constant concentration of the anti-
body. Conditions for incubation with secondary antibody
and colorimetric reactions were the same as described
above. Readings at OD490 were made and plotted against
the log dilutions of the antigen.
Specificity of the antibody by immunoprecipitation
About 100 embryonic metanephroi were dissected out
from mouse fetuses at day-13 of gestation, and maintained
in an organ culture system, as detailed previously [33, 40].
Briefly, the harvested metanephric explants were placed on
an 0.8-mm pore size filter, floated onto a serum-free
medium, composed of equal volumes of DME and Ham’s
nutrient mixture F12, and penicillin (100 mg/ml), strepto-
mycin (100 mg/ml) and transferrin (50 mg/ml; Sigma Chem-
ical Co., St. Louis, MO, USA). The explants were cultured
in a CO2 incubator for four days, and then radiolabeled
with [35S]methionine (0.25 mCi/ml) for 16 hours prior to
the termination of the culture. After a brief rinse with the
culture media, they were lysed in an extraction buffer (50
mM Tris-HCl, pH 7.5, 50 mM NaCl, 10 mM EDTA, 0.2%
Na2N3, 1% Triton X-100, 0.25 mM dithiothreitol, 10 mM
benzamidine-HCl, 10 mM e-amino-n-caproic acid and 2 mM
phenylmethanesulfonyl fluoride) by shaking vigorously for
two hours at 4°C. The extract was centrifuged at 10,000 g
for 30 minutes at 4°C, and the supernatant was saved.
Immunoprecipitation was performed by adding to 5 ml of
polyclonal anti-MT-1-MMP antibody to 0.5 ml (;5 3 106
dpm) of the supernatant. The mixture was gently swirled in
an orbital shaker for 15 hours at 4°C. After addition of 80
ml of protein-A Sepharose 4B (Pharmacia LKB Biotech-
nology, Piscataway, NJ, USA), the antigen-antibody mix-
ture was further incubated for one hour at 4°C. The
complex was then microfuged for 10 seconds, and washed
three times with the extraction buffer. The immunoprecipi-
tated complex was dissolved in a sample buffer (4% SDS,
150 mM Tris-HCl, pH 6.8, 20% glycerol, 0.1% bromophenol
blue and 10% b-mercaptoethanol), boiled for five minutes,
and subjected to 10% SDS-PAGE. The gels were fixed in
10% acetic acid and 10% methanol, treated with 1 M
salicylic acid, vacuum dried and autoradiograms prepared.
Two control immunoprecipitation experiments were also
performed. In the first experiment, polyclonal anti-MT-1-
MMP antibody previously absorbed with the synthetic
peptide was used for immunoprecipitation; in the second
experiment, pre-immune rabbit serum was used as a con-
trol.
Expression of MT-1-MMP, MMP-2 and TIMP-2 by
tissue immunofluorescence
Embryonic (days 213 and 217) and newborn mouse
kidneys were snap-frozen in chilled isopentane and embed-
ded in OCTy compound (Miles Laboratories, Inc., Elkhart,
IN, USA). Four-micrometer-thick cryostat sections were
prepared and air dried. Sections were washed with 0.01 M
PBS, pH 7.4, incubated with polyclonal anti-MT-1-MMP,
with 1:100 dilution, for 30 minutes in a humidified chamber
at 37°C. After washing with PBS, sections were re-incu-
bated with fluoresceinated goat anti-rabbit IgG antibody
for 30 minutes. They were re-washed with PBS, covered
with a drop of buffered glycerol, coverslip mounted, and
examined with an ultraviolet microscope equipped with
epi-illumination. Similarly, immunofluorescence studies
were performed by using polyclonal anti-MMP-2 and
-TIMP-2 antibodies.
RESULTS
Characterization of embryonic mouse kidney MT-1-MMP
cDNA clones
Four overlapping clones with EcoRI cloning sites were
isolated from embryonic cDNA libraries (Fig. 1). Clone #2
had the initiation codon, while clone #1 had the termina-
tion codon. The open reading frame included 1746 nucle-
otides and a deduced translated product of 582 amino
acids. Mouse MT-1-MMP had ;86% and ;96% sequence
homology with human MT-1-MMP [15] at the nucleotide
and amino acid levels, respectively. In addition to embry-
onic renal MT-1-MMP cDNA, partial-length MT-1-MMP
cDNAs from other organs of the one-week-old mouse,
including brain, heart, liver, lung and placenta were gener-
ated by PCR using MT-SE and MT-AS primers. The
resulting ;879 bp DNA products were subcloned and
sequenced. All the PCR-generated cDNA clones had iden-
tical nucleotide sequences to MT-1-MMP, isolated from
embryonic mouse renal cDNA library, suggesting that there
are no isoforms of MT-1-MMP in mouse tissues. Moreover,
the 114 bp cDNA clone isolated from mouse placental
cDNA library [41] had an identical sequence with the PCR
products examined in this study. However, the unpublished
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whole-length placental MT-1-MMP cDNA (Genbank ac-
cession # X83536) has ;96% homology at the amino acid
level with our clone, isolated from newborn mice cDNA
library. These differences may be difficult to address in view
of the unpublished nature of the placental cDNA data. In
the newborn renal cDNA, no polyadenylation site
(AATAAA) or A(U)nA mRNA instability motifs were
present up to ;590 bp downstream from the 39 end of the
translated product of mouse MT-1-MMP (Genbank acces-
sion # U54984).
The amino acid (aa) sequence analysis of MT-1-MMP
indicated that it had structural domains similar to other
MMPs [9, 15, 16]. They included a signal/pro-peptide (aa:
1-111), a catalytic domain (aa: 112-283) with a Zn11-
binding site (HELGHALGLEH) (Fig. 2A, shaded box)
essential for the enzyme activity, a proline-rich segment
potentially functioning as a hinge region (aa: 284-318) and
a hemopexin-like repeat region (aa: 319-582). Like human
MT-1-MMP, the mouse MT-1-MMP had other unique
characteristics, which included three insertions [15, 16].
The first insertion consisted of 11 amino acids between the
pro-peptide and the catalytic domains (aa: 101-111), which
included a basic amino-acid-rich (RRKR) sequence (Fig.
2A) corresponding to the furin enzyme recognition site
[18]. The second consisted of 8 amino acids in the catalytic
domain (aa: 163-170). The third insertion consisted of 60
amino acids at the C terminal, which included a hydropho-
bic domain (aa: 537-559) (Fig. 2B), as revealed by the
hydropathic analyses (Fig. 2C). This hydrophobic domain is
regarded as the putative transmembrane segment of MT-
1-MMP, which is followed by a small intracellular domain.
Another hydrophobic domain, stretching between 12 to 25
amino acids, corresponded to the putative signal peptide of
MT-1-MMP (Fig. 2B). In the entire open reading frame of
MT-1-MMP, only two potential N-linked glycosylation sites
were observed (Fig. 2A).
Developmental mRNA expression of mouse MT-1-MMP
At day-19 (newborn), Northern blot analyses revealed a
single ;4.5 Kb mRNA MT-1-MMP transcript in various
tissues (Fig. 3A), suggesting an absence of alternatively
spliced isoforms. An abundant expression of MT-1-MMP in
placenta, kidney, heart and lung was observed. Expression
in the liver was markedly reduced relative to other tissues
examined and no MT-1-MMP transcripts were detectable
in the brain tissue sample. Northern blot analyses of
mRNA, isolated from kidneys during the embryonic and
neonatal periods, also revealed a single ;4.5 Kb transcript
(Fig. 3B). The mRNA expression in the kidney steadily
increased from days 213 to 219 of gestation, and it
gradually decreased during the postnatal period, suggesting
that MT-1-MMP is developmentally regulated during the
organogenesis of the metanephros. The highest mRNA
expression was detected during the late stages of murine
gestation, that is, in day-17 and day-19 (newborn) kidneys.
Since MT-1-MMP is an activator of pro-MMP-2 and the
activity of both MT-1-MMP and MMP-2 are selectively
blocked by TIMP-2, the mRNA expression of MMP-2 and
Fig. 3. Northern blot analyses of mouse MT-1-MMP mRNA expressed in
different organs at day-19 of gestation (A), and various embryonic and
post-natal developmental stages of the kidney (B). Poly(A)1 RNAs were
denatured with glyoxal, subjected to 1% agarose gel electrophoresis,
transferred to nylon membranes, and hybridized with [a-32P]dCTP radio-
labeled MT-1-MMP and b-actin cDNA inserts. A major transcript of 4.5
kb for mouse MT-1-MMP is observed, which is highly expressed in
placenta, kidney, lung and heart (A). It is also weakly expressed in the
liver, and its expression is undetectable in the brain. Also, a single major
band of 4.5 kb for mouse MT-1-MMP is observed at various developmen-
tal stages of the kidney, and its expression is highest during the later stages
of the embryonic gestation, that is, day-17 and day-19. Similarly, a
developmentally regulated expression of mouse MMP-2 (4.0 kb) and of
TIMP-2 (23.5 kb) is observed in kidneys of embryonic and post-natal
mice, although their expression is relatively less compared to MT-1-MMP
(B). The Figure of the smaller 1.0 kb transcript of TIMP-2 is not included,
but it also exhibited a developmentally regulated expression, which
paralleled to that of its larger 3.5 kb transcript. The expression of b-actin
in various organs and developmental stages of kidney remains constant.
Lanes 13 days, 17 days, NB, 1 week, 2 weeks, and 3 weeks indicate
poly(A)1 RNA of 13-day- and 17-day-old fetuses, and newborn, 1-week-,
2-week-, and 3-week-old mice.
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TIMP-2 in kidneys, harvested from embryonic and postna-
tal periods, were also determined. The developmentally
regulated mRNA expression of both the MMP-2 (;4.0 Kb)
and TIMP-2 (;3.5) was observed (Fig. 3B). For MMP-2
mRNA this regulated expression pattern paralleled that of
MT-1-MMP, and it was highest in the day-17 and day-19
kidneys. In contrast, TIMP-2 mRNA expression lagged
slightly behind both MT-1-MMP and MMP-2 expression,
with the most intense signals obtained during the first week
of neonatal development. The b-actin mRNA expression
was essentially constant in various tissues during the mu-
rine embryonic and postnatal life (Fig. 3 A, B).
In situ hybridization studies were carried out to deter-
mine the spatio-temporal expression of MT-1-MMP in
kidney tissues, harvested at days-13 to -19 of gestation. At
day-13, the MT-1-MMP was expressed equally in the
ureteric bud branches and epithelial elements of the devel-
oping nephrons (Figs. 4 A, C). MT-1-MMP expression was
not observed in the metanephric mesenchyme. At day-17,
the MT-1-MMP mRNA signal was confined to the renal
cortex, consisting of tubular and glomerular elements (Fig.
4 D, F). The renal medullary collecting ducts, derived from
the ureteric bud branches, also expressed MT-1-MMP. The
remaining medullary interstitium, derived from the meta-
nephric mesenchyme, did not express MT-1-MMP (Fig. 4
D, F). At day-19 (newborn), the MT-1-MMP mRNA was
confined cortical and medullary tubules (Fig. 4 G, I). The
expression in the glomeruli was markedly reduced (Fig. 4
G, I). The adjacent tissue sections of metanephric explants
hybridized with sense probe had negligible mRNA signals
(Fig. 4 B, E, H). The expression of MMP-2 and TIMP-2
mRNA was mainly confined to the metanephric mesen-
chyme, and was identical to that reported by Reponen et al
[38], and therefore, the Figure depicting their expression is
not included.
Anti-MT-1-MMP antibody characterization
Specificity of the polyclonal antibody, directed against
the synthetic peptide (KVEPGYPKSALRDWMG) of MT-
1-MMP (Fig. 2A), was determined by immunoprecipitation
and ELISA methods. The extract of [35S]methionine-la-
beled metanephric explants was immunoprecipitated and
subjected to SDS-PAGE analyses. A 63 kD band, similar to
the size of human MT-1-MMP [14], was observed (Fig. 5A,
lane 1). No autoradiographic band was observed in the
pre-immune serum (Fig. 5A, lane 2). Also, the antibody
pre-absorbed with the synthetic peptide failed to immuno-
precipitate de novo synthesized MT-1-MMP, and no band
of radioactivity was observed in the SDS-PAGE autoradio-
gram (Fig. 5A, lane 3). The specificity of the antibody was
also assessed by ELISA in which a fixed amount of antigen,
that is, synthetic peptide, and serial logarithmic dilutions of
the antibody were used. A proportional decrease in OD490
readings was observed with increasing dilutions of the
antibody (Fig. 5B). To confirm the antibody specificity, an
inhibition ELISA assay was performed in which synthetic
peptide was used as a competitive antigen. With increasing
dilutions of the competitive antigen, a proportional in-
crease in OD490 readings was observed (Fig. 5B, dotted
line), confirming the specificity of anti-MT-1-MMP anti-
body. The specificities of the anti-MMP-2 and anti-TIMP-2
antibodies have been detailed previously [42–44].
Immunofluorescence studies
At day-13, MT-1-MMP was seen localized to the plas-
malemma of the epithelia of ureteric bud branches and
nascent nephrons, that is, tubules, and comma- and S-
shaped bodies of the metanephros (Fig. 6A). In addition,
the MT-1-MMP expression was seen in the induced meta-
nephric mesenchyme (Fig. 6A, arrowheads). The immuno-
reactivity was absent in the metanephric mesenchyme. At
day-17, MT-1-MMP was seen expressed in the tubular
epithelia of the renal cortex, the collecting tubules and
ducts in the medulla, and in the residual induced meta-
nephric mesenchyme (Fig. 6B, arrowheads). No expression
was seen in the medullary interstitium. The glomeruli
displayed a weak immunoreactivity, and the expression was
undetectable in the intra-renal vasculature. The spatial
distribution of MT-1-MMP at day-19 (newborn) was essen-
tially the same as on day-17, except the degree of expres-
sion was relatively less (Fig. 6C). The spatio-temporal
expression of MMP-2 was identical to that of the MT-1-
MMP in the kidneys, harvested during various stages of
gestation, that is, day-13 to day-19 (Fig. 6 D–F). The
TIMP-2 was also found co-distributed with MT-1-MMP
and MMP-2, and it exhibited spatio-temporal expression in
the embryonic and newborn kidneys (Fig. 6 G–I). Its
expression was notably less relative to MT-1-MMP and
MMP-2 in metanephroi from day-13 and day-17 of gesta-
tion, but increased to comparable levels in the tubular
epithelia of the renal cortex by day-19, and remained
undetectable in the glomeruli and the medullary intersti-
tium (Fig. 6I).
DISCUSSION
To date, few studies have been reported in the literature
which describe the developmental regulation of MMPs
during the morphogenesis of various embryonic organs
[45–47]. Werb et al initiated studies on the developmental
biology of the peri-implantation embryos, and reported the
expression of MMP3 and TIMP-1 in early stages of embry-
onic development [45]. These investigators have also estab-
lished the role of TIMP-1 and TIMP-3 in decidual remod-
eling [46]. Convincing data relevant to organogenesis have
been derived from studies of transgenic mice in adult life,
where an overexpression of MMP-3 resulted in an accen-
tuated branching morphogenesis of the mammary gland
[48, 49]. Along these lines, the increasing mRNA expres-
sion of MMP-2 in stromal cells suggest its relevance in the
organogenesis of other organ systems during post-natal life
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Fig. 4. Dark-field light microscopic autoradiograms of in situ hybridization of kidneys (A, B, D, E, G and H) of mouse MT-1-MMP at day-13 (A and
B), day-17 (D and E) and day-19 (G and H) of the gestation. (C, F and I) Corresponding light micrographs of panels A, D and G, respectively. The
tissue sections in panels A, D and G were hybridized with [33P]UTP-labeled antisense-riboprobe generated from mouse MT-1-MMP cDNA. The
adjacent tissue sections in panels B, E and H were hybridized with the sense-riboprobe. At day-13 (A), MT-1-MMP is expressed in ureteric bud branches
(U) and nascent developing nephrons (white arrows). No message is seen in the metanephric mesenchyme (m). At day-17 (panel D), the expression is
mainly observed in renal cortex and collecting ducts (C) in the medulla. The message is not seen in the remaining medullary interstitium, derived from
the metanephric mesenchyme (m). At day-19 (newborn; panel G) , the expression is mainly confined to the cortical and medullary tubules (T). The large
black and white arrows in panels D and G indicate a very weak expression in the renal glomeruli. The arrowheads in panels B, E and H outline the
boundaries of the metanephroi.
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[50]. Preliminary results of RT-PCR studies indicating the
presence of MT-1-MMP in the embryonic metanephros
gave an impetus to conduct this investigation of its struc-
tural analysis, its spatio-temporal distribution in organ
development and relationship of this activator of pro-
MMP-2 to the expression of MMP-2 and its inhibitor,
TIMP-2.
Analysis of the primary structure reveals that murine
MT-1-MMP (Fig. 2), isolated from embryonic kidney, has
substantial homology with the human counterpart ex-
pressed in epithelial tumors [15]. Since MT-1-MMP is
expressed in the human neoplastic cells, it has been impli-
cated in the invasion and migration of epithelial tumors
into the stroma [15, 51]. Conceivably, in an analogous
manner, MT-1-MMP may facilitate migration of the ure-
teric bud branches into the loose embryonic mesenchyme
while being bound via its putative hydrophobic transmem-
brane segment (Fig. 2C) to the cell membranes of the
epithelia lining the advancing tips of the ureteric epithelial
buds. In such a cell migratory process, one would also
expect local degradation of the matrix by the activated form
of MT-1-MMP [52]. Apparently, its activation could occur
readily in the metanephros since the catalytic domain of
MT-1-MMP is preceded by a RXKR recognition motif for
furin, an endopeptidase that contributes to the proteolytic
processing of numerous fetal proteins [19] and is widely
distributed in various embryonic tissues, including the
metanephros [53].
The contention that MT-1-MMP may be involved in the
organogenesis of various tissues is supported by the fact
that it is highly expressed in the embryonic metanephros,
and is developmentally regulated (Fig. 3). The fact that
mRNA expression seems to be high during the mid to late
stages of gestation, the period when organogenesis is at its
peak, lend further support to this notion. It is interesting to
note that the expression of MMP-2 parallels the expression
of MT-1-MMP, suggesting that they may have a conjoint
role in the morphogenesis of the kidney. Such a parallel
co-expression of MT-1-MMP and MMP-2 has been ob-
served in ossifying tissues during embryogenesis [54]. Fur-
thermore, the findings of this study indicate the spatial
restriction of MT-1-MMP mRNA expression to the epithe-
lial components of the fetal kidney (Fig. 4), while the
MMP-2 is concentrated in the surrounding mesenchyme
[38]. MT-1-MMP is known to function as an activator of
pro-MMP-2 [15]. The demonstration that MT-1-MMP
mRNA localization in the epithelial compartment and
MMP-2 in the mesenchymal reflects the important role of
epithelial:mesenchymal interactions, prevalent during em-
bryogenesis, in mediating MMP-2 activation and initiating
subsequent matrix degradation. Such paracrine/juxtacrine
interactions may indeed be feasible in view of the results of
immuno-histochemical studies in which specific antibodies
were utilized (Fig. 6). The findings of these studies indi-
cated that MT-1-MMP and MMP-2 are co-expressed in the
epithelia of ureteric bud branches, and that like mRNA
expression the protein expression is also developmentally
regulated (Fig. 4). Although, the spatial mRNA expression
of MT-1-MMP and MMP-2 differ, the immuno-localization
of MMP-2 to the ureteric bud epithelia may be related to its
binding to the plasmalemmal MT-1-MMP after it being
secreted out from mesenchymal cells of the metanephros.
Fig. 5. (A) SDS-PAGE autoradiogram of [35S]methionine-labeled metanephric glycoproteins, immunoprecipitated with rabbit anti-MT-1-MMP. The
metanephric explants, harvested at day-13, were maintained in an organ culture and labeled with [35S]methionine. Membrane proteins were extracted,
and immunoprecipitated proteins were subjected to 10% SDS-PAGE under reducing conditions. The de novo synthesized MT-1-MMP is visualized as
a band of Mr 63 kD after immunoprecipitation with anti-MT-1-MMP, as indicated by an arrowhead in lane 1. No band is seen in the radiolabeled
membrane proteins immunoprecipitated with preimmune serum (lane 2) or with anti-MT-1-MMP previously absorbed with the synthetic peptide (lane
3). The small arrow indicates the sample application site. (B) Enzyme-linked immunosorbent assay (ELISA) and competitive inhibition-ELISA profiles
of MT-1-MMP antibody. A decrease in OD490 readings is observed with increasing log dilutions of anti-MT-1-MMP antibody (solid line); while an
increase in OD490 readings is observed with increasing log dilutions of the synthetic peptide (dotted line), confirming the specificity of the antibody.
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Such a translocation of MMP-2, that is, from stromal to
epithelial cells, has been suggested by in situ hybridization
studies in various human neoplasms as well [55, 56]. It is
believed that such a translocation may facilitate the inva-
sion and local metastasis of epithelial tumors into the
surrounding stroma upon activation of MMP-2 by MT-1-
MMP [30]. In this regard, it is interesting to note that an
increased expression of both MT-1-MMP and MMP-2 has
been observed in human neoplasms with metastatic poten-
tial [57, 58]. The inhibitor of MMP-2, that is, TIMP-2,
which binds to MMP-2 with 1:1 molar stoichiometry [27],
may limit the invasion of cancer cells into the stroma since
an increased expression of TIMP-2 has been reported to
reduce the metastatic potential of the invasive tumor cells
[10, 59]. Thus, it is interesting to note that maximal TIMP-2
expression in the developing metanephros is slightly de-
layed with respect to MT-1-MMP and MMP-2, and occurs
during the first week of post-natal development (Fig. 3). It
has been postulated that formation of a tri-macromolecular
complex of MT-1-MMP:MMP-2:TIMP-2 [22, 23] may be
essential for the cell mediated activation of pro-MMP-2
and participation in processes that regulate epithelial:
mesenchymal interactions, including tumor invasion and
embryogenesis. The fact that TIMP-2 was co-expressed
with MT-1-MMP and MMP-2 in embryonic epithelia, and
that it was developmentally regulated (Figs. 3, 4, and 6)
would be suggestive of a role in organogenesis of the
kidney. However, direct evidence of tri-macromolecular
complex formation, that is, MT-1-MMP:MMP-2:TIMP-2,
and the role of TIMP-2 in the formation of such a complex
in the embryonic metanephros remains to be investigated.
Although the data of the present investigation implicates
Fig. 6. Immunofluorescence photomicrographs of metanephric tissues stained with anti-MT-1-MMP (A–C), anti-MMP-2 (D–F), and anti-TIMP-2
(G–I), harvested at day-13 (A, D and G), day-17 (B, E and H) and day-19 (C, F and I). At day-13 (panel A), the immunoreactivity of MT-1-MMP is
observed in the ureteric bud branches (U), nascent nephrons (n) and induced mesenchyme (arrowheads). No immunostaining is observed in the
uninduced metanephric mesenchyme (m). At day-17 (panel B), MT-1-MMP is localized in the developing glomeruli and tubules of the renal cortex, the
collecting ducts of the medulla and residual induced mesenchyme (arrow heads). The expression is absent in the medullary interstitium, derived from
the metanephric mesenchyme (m). At day-19 (newborn) (panel C), MT-1-MMP expression is seen in the tubules of the cortex and in the collecting ducts
of the medulla, although the degree of expression is relatively less compared to day-17. The expression in the glomeruli (g) is almost negligible. The
immunoreactivity of MMP-2 is also observed in the ureteric bud branches (U) and nascent nephrons (n) at day-13 (panel D). At day-17 (panel E),
MMP-2 is expressed in the renal cortex and collecting ducts of medulla. At day-19 or in the newborn (panel F), its staining is seen mainly in the collecting
ducts of the medulla and tubules in the cortex, however, the immunoreactivity is not clearly visualized in the glomeruli (g). The spatio-temporal
expression of TIMP-2 (panels G–I) in the embryonic and neonatal kidneys is similar to that of MT-1-MMP and MMP-2. However, the expression is
relatively less, and it is clearly absent in the glomeruli (g) of the newborn kidneys (panel I). The small white arrows in panels B, E and H indicate the
absence of immunoreactivity in the lumina of the renal medullary collecting ducts.
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the role of MMP-2, an integral component of the tri-
macromolecular complex, in metanephric development,
but the anti-MMP-2 antibody fails to inhibit the branching
morphogenesis of the metanephros [47]. This failure may in
part be related to the nature of the antibody used, that is,
blocking versus non-blocking type, or to the poor accessi-
bility of the antibody to the deeply situated metanephric
ureteric bud branches or to the gestational stage of the
metanephroi employed. In any event, certain other MMPs,
such as MMP-1, certainly have been shown to play a role in
the branching morphogenesis, at least in the MDCK cell
culture systems. In these cell culture systems, Nigam and
his colleagues [60, 61] have been able to demonstrate a
parallel rise or fall in the mRNA expression of MMP-1 with
inhibition or stimulation of branching morphogenesis un-
der the influence of transforming growth factor-beta
(TGF-b) or ligands of epidermal growth factor receptor,
such as TGF-a. Since TGF-a and TGF-b regulate the
expressions of matrix proteins, these studies also suggest
that the biology of the growth factors and of the ECM
macromolecules, with respect to metanephric develop-
ment, is intricately linked.
Finally, the role of secretory type of MMPs, described as
collagenases in the older literature, in organotypic epithe-
lial:mesenchymal interactions was proposed three decades
ago by Grobstein and and his colleagues [62, 63]. They
postulated that a concentration gradient of ECM proteins,
generated by the action of MMPs, is essential to the cleft
formation and lobulogenesis of glandular tissues. Direct
evidence implicating a differential gradient of collagen
fragments initiating cleft formation and lobulogenesis was
provided by studies in which treatment with bacterial
collagenase perturbed the branching morphogenesis of
salivary glands [64–66]. In contrast, collagenase inhibitors
stimulated branching morphogenesis in these assays. Fur-
ther support for the role of secreted-type of MMPs in
morphogenesis of glandular tissues was obtained by elegant
transgenic studies of stromelysin-1 function in mammary
gland morphogenesis, as mentioned previously [48, 49].
Similarly, transgenic or knockout experiments are needed
to elucidate the role MT-1-MMP in the organogenesis of
the metanephros, and this would be subject of future
investigations.
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